Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

Movement Disorders

Volumn 11, Issue 1, 1996, Pages 91-94

  Blanchet, P J ^a   Grondin, R ^a   Bedard P J ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine D1 receptor; Dyskinesia, drug induced; Parkinsonism; Wearing off

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; QUINPIROLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DYSKINESIA; FEMALE; MOTOR DYSFUNCTION; MYOCLONUS; NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENZAZEPINES; BRAIN; DOPAMINE AGENTS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE D1;

EID: 0030067701     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110117     Document Type: Article

References (19)

1. 3H]spiperone binding. Brain Res 1986;379:294-299.
2. 2 receptors in MPTP - induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 1993,265:1387-1391.
3. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in MPTP monkeys. J Pharmacol Exp Ther 1993;267:275-279.
4. 1 agonist, CY 208-243, in de novo patients with Parkinson's disease. Mov Disord 1992;7: 239-243.
5. 1 receptor agonists for stimulating adenylyl cyclase in 1 squirrel monkey and rat. Eur J Pharmacol 1993;246:39-44.
6. 1 receptor efficacy. Eur J Pharmacol 1990;188:335-347.
7. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990;40:927-933.
8. A receptors. Neurosci Lett 1993;163:31-55.
9. 2 receptors in the monkey brain in MPTP - induced parkinsonism. Brain Res 1993;602:290-303.
10. 2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv Neurol 1993;60:113-118.
11. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
12. Hallett M. Physiology of basal ganglia disorders: an overview. Can J Neurol Sci 1993;20:177-183.
13. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment. Mov Disord 1990;5:100-108.
14. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-371.
15. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196.
16. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinc (MPTP): seven cases. Neurology 1985;35: 949-956.
17. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
18. Robertson HA, Peterson MR, Worth GG. Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243. Brain Res 1992;593:332-334.
19. Calon F, Goulet M, Blanchet PJ, et al. Levodopa or D-2 agonist dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABA-A receptors in the striatopallidal complex. Brain Res 1995;680:43-52.